Comparison · NCT03487445-sae
Selatogrel 8 mg vs Selatogrel 16 mg: serious adverse events
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Selatogrel 8 mg vs Selatogrel 16 mg: serious adverse events. Trial comparisons, record NCT03487445-sae. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT03487445-sae
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.0417 | 0.00739 | 0.202 | wilson | |
| Risk in group 2 | 0.0435 | 0.00772 | 0.21 | wilson | |
| Risk difference, group 1 minus group 2 | -0.00181 | -0.172 | 0.163 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.958 | 0.0636 | 14.4 | log | |
| Odds ratio, group 1 over group 2 | 0.957 | 0.0563 | 16.3 | log | |
| Number needed to treat, for one fewer participant with a serious adverse event on Selatogrel 8 mg than on Selatogrel 16 mg | 552 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Selatogrel 8 mg | A single 8 mg dose of selatogrel (ACT-246475) was administered via a single subcutaneous injection in the thigh. | 1 | 24 | EG000 |
| Group 2 | Selatogrel 16 mg | A single 16 mg dose of selatogrel (ACT-246475) was administered via a single subcutaneous injection in the thigh. | 1 | 23 | EG001 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, serious adverse events
- Time frame
- Treatment emergent adverse events (TEAEs) were those adverse events with onset after study drug administration and up to 48 hours after study treatment administration.
Source ClinicalTrials.gov
Trial
- Title
- A Medical Research Study to Evaluate the Effects of ACT-246475 in Adults With Heart Attack
- NCT number
- NCT03487445
- Phases
- PHASE2
- Conditions
- Acute Myocardial Infarction
- Interventions
- Selatogrel 8 mg, Selatogrel 16 mg
- Lead sponsor
- Viatris Innovation GmbH
- Results first posted
- 2021-08-25
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT03487445?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT03487445-sae